Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Leukemia, Myeloid, Acute 198Leukemia, Lymphocytic, Chronic, B-Cell 48Myelodysplastic Syndromes 39Precursor Cell Lymphoblastic Leukemia-Lymphoma 32Recurrence 27Leukemia 26Lymphoma, Mantle-Cell 22Leukemia, Myelomonocytic, Chronic 16Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 15Leukemia, Biphenotypic, Acute 15Lymphoma, Follicular 14Lymphoma, Non-Hodgkin 12Lymphoma, Large B-Cell, Diffuse 12Lymphoma 12Burkitt Lymphoma 12Lymphoma, B-Cell, Marginal Zone 10Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Neoplasm, Residual 9Hematologic Neoplasms 9Multiple Myeloma 7Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 6Myeloproliferative Disorders 6Waldenstrom Macroglobulinemia 5Neoplasms 5Lymphoma, B-Cell 5Leukemia, Myeloid 5Blastic Plasmacytoid Dendritic Cell Neoplasm 5Leukemia, B-Cell 4Immunoglobulin Light-chain Amyloidosis 4Blast Crisis 4

Interventions

fludarabine phosphate 6Whole-Body Irradiation 5Mycophenolic Acid 5fludarabine 4Peripheral Blood Stem Cell Transplantation 4Cyclosporins 4Cyclosporine 4Cyclophosphamide 4ruxolitinib 3Cytarabine 3venetoclax 2itacitinib 2duvelisib 2carmustine, poliferprosan 20 drug combination 2Stem Cell Transplantation 2Sirolimus 2Melphalan 2Etoposide 2Carmustine 2Alemtuzumab 2thymoglobulin 1romidepsin 1nelarabine 1letermovir 1Tacrolimus 1Mitoxantrone 1INCB039110 1Hematopoietic Stem Cell Transplantation 1Everolimus 1Depsipeptides 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Leukemia, Prolymphocytic, T-Cell × venetoclax × Clear all
NCT07311746 2025-12-31

Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Not yet recruiting
36 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Prolymphocytic, T-Cell

NCT06810778 2025-07-15

Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Jonsson Comprehensive Cancer Center

Phase 1/2 Recruiting
12 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Leukemia, Prolymphocytic, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡